New ALS Drug Raises Canadians’ Hopes

New ALS Drug Raises Canadians’ Hopes
SHARE

The amoyotrophic lateral sclerosis is a common disease in Canada. Unfortunately, many people suffer from this disease and the worst part is that they might have found the cure but the state won’t let them use it freely, as they wish.

The amoyotrophic lateral sclerosis, or ALS, is difficult and complex disease and this is why the people who suffer from it spend lots of money on getting a specific drug from abroad Sold under the name of Radicava or Radicut, edaravone can have a positive effect on people with ASL.

The study that gave Canadians hope is the one that was recently carried out in Japan. Apparently, the study showed that the drug called edaravone slowed down the dangerous disease by 33%. This is actually an impressive number, given the seriousness of the disease. Moreover, only a small number of people with amoyotrophic lateral sclerosis experienced secondary effects like headache, bruising, inflammation of the skin or breathing issues after taking the drug.

Due to the fact that it is a neurodegenerative disease, the people who suffer from it lose some of the most important functions and abilities of the human body, namely speaking, walking, breathing and moving. After they have been diagnosed with the disease the patients will eventually die in 3- 5 years.

But the Japanese study gave everyone hope and this is why in May the U.S. Food and Drug Administration made the drug legal. Unfortunately, in Canada it still isn’t legal. The state is making it even more difficult for the people with ASL. A woman who suffers from ASL had to travel to Japan last year to get the infusions. She spent 4.000$ on different expenses.

At least now, Health Canada lets people get the substance from abroad, but it is still a long way to making the drug more accessible for the people who are in need.


SHARE

Share this post

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.